Christa Pawlowski turns Ohio research into lifesaving technology
Christa Pawlowski turns Ohio research into lifesaving technology
https://www.ohiotechnews.com/christa-pawlowski-turns-ohio-research-into-lifesaving-technology/
Publish Date: 2026-01-29 06:36:00
Source Domain: www.ohiotechnews.com
Spotlights
Haima Therapeutics co-founder Christa Pawlowski is developing SynthoPlate, a synthetic, shelf-stable drug that stops severe bleeding. By transforming Case Western research into lifesaving tech, she is helping establish Ohio as a premier hub for scaling global life science companies.
Severe bleeding due to traumatic injury, surgery, and bleeding disorders is still the #1 cause of preventable death. Dr. Christa Pawlowski is developing a solution that doesn’t depend on donated blood.
As co-founder and Chief Operating Officer of Haima Therapeutics, Pawlowski leads the development of SynthoPlate, a synthetic, platelet-inspired drug that helps the body stop bleeding quickly and safely. The technology amplifies the body’s natural clotting response right at the site of injury, and it’s shelf-stable, easy to administer, and designed to work where traditional blood products fall short, from ambulances and operating rooms to remote environments and battlefields.
Pawlowski is a biotechnology leader with more than 15 years of experience turning scientific ideas into real-world medical solutions. Previously, she served as Director of Operations at BioMotiv, a biotech accelerator, where she managed two startup companies developing new treatments for cancer and heart-lung diseases, including one that later partnered with a global pharmaceutical company.
She earned her PhD in Biomedical Engineering from Case Western Reserve University, where the foundational research behind SynthoPlate was born. Now she’s advancing that technology through an Ohio-based company, keeping innovation, jobs, and investment rooted in the state.
Beyond her work at Haima, Pawlowski is committed to helping Ohio grow its reputation…
